In studies with experimental gliomas, the treatment with GRPR antagonists increased the survival time by inhibiting the growth of xenografts of human glioblastomas cell lines (U-87G,U-373MG) in nude mice (159, 160). This evidence concerns the gene GRPR and central nervous system cancer.